Park Ha Biological Technology Co., Ltd.
PHH · NASDAQ
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.00 | 0.00 |
| FCF Yield | 333,931.68% | 39,641.60% | 545,960.31% | -194,948.47% |
| EV / EBITDA | -0.58 | -0.83 | -2.48 | 0.08 |
| Quality | ||||
| ROIC | 30.37% | 81.59% | 111.65% | 92.27% |
| Gross Margin | 91.81% | 87.35% | 73.47% | 66.58% |
| Cash Conversion Ratio | 2.01 | 0.15 | 7.54 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.46% | 38.23% | -83.85% | -88.56% |
| Free Cash Flow Growth | 742.38% | -92.74% | 380.05% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.58 | -0.83 | -2.49 | 0.08 |
| Interest Coverage | 0.00 | 0.00 | 1,015.59 | -419.60 |
| Efficiency | ||||
| Inventory Turnover | 2.73 | 3.24 | 5.41 | 0.98 |
| Cash Conversion Cycle | 258.64 | -13.37 | 264.64 | 297.72 |